KR20220090512A - 액체암의 치료를 위한 조성물 및 방법 - Google Patents
액체암의 치료를 위한 조성물 및 방법 Download PDFInfo
- Publication number
- KR20220090512A KR20220090512A KR1020227013872A KR20227013872A KR20220090512A KR 20220090512 A KR20220090512 A KR 20220090512A KR 1020227013872 A KR1020227013872 A KR 1020227013872A KR 20227013872 A KR20227013872 A KR 20227013872A KR 20220090512 A KR20220090512 A KR 20220090512A
- Authority
- KR
- South Korea
- Prior art keywords
- cell
- cells
- immune
- car
- tada
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/13—B-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/418—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4214—Receptors for cytokines
- A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4214—Receptors for cytokines
- A61K40/4217—Receptors for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Gram-positive bacteria
- C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Oncology (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962907254P | 2019-09-27 | 2019-09-27 | |
| US62/907,254 | 2019-09-27 | ||
| PCT/US2020/052822 WO2021062227A2 (en) | 2019-09-27 | 2020-09-25 | Compositions and methods for treatment of liquid cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220090512A true KR20220090512A (ko) | 2022-06-29 |
Family
ID=75166843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227013872A Pending KR20220090512A (ko) | 2019-09-27 | 2020-09-25 | 액체암의 치료를 위한 조성물 및 방법 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12594301B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4034138A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7615134B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220090512A (cg-RX-API-DMAC7.html) |
| CN (2) | CN115279398B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020355222A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3155667A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021062227A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210055733A (ko) | 2018-09-07 | 2021-05-17 | 빔 테라퓨틱스, 인크. | 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법 |
| US12600971B2 (en) | 2019-02-13 | 2026-04-14 | Beam Therapeutics Inc. | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| US12594301B2 (en) | 2019-09-27 | 2026-04-07 | Beam Therapeutics Inc. | Compositions and methods for treatment of liquid cancers |
| EP4211245A1 (en) * | 2020-09-14 | 2023-07-19 | Vor Biopharma Inc. | Compositions and methods for cd5 modification |
| WO2022061115A1 (en) * | 2020-09-18 | 2022-03-24 | Vor Biopharma Inc. | Compositions and methods for cd7 modification |
| AU2021347359A1 (en) | 2020-09-25 | 2023-05-18 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
| US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| EP4271798A1 (en) | 2020-12-30 | 2023-11-08 | CRISPR Therapeutics AG | Compositions and methods for differentiating stem cells into nk cells |
| CN115443333B (zh) * | 2021-04-27 | 2025-04-25 | 上海驯鹿生物技术有限公司 | 一种基因编辑的造血干细胞及其与car-t细胞的联合应用 |
| WO2022240858A1 (en) | 2021-05-10 | 2022-11-17 | Mammoth Biosciences, Inc. | Effector proteins and methods of use |
| US20230279352A1 (en) * | 2021-08-24 | 2023-09-07 | Astrazeneca Ab | Methods for generating primary immune cells |
| WO2023034475A1 (en) * | 2021-09-01 | 2023-03-09 | Arbor Biotechnologies, Inc. | Cells modified by a cas12i polypeptide |
| MX2024003887A (es) | 2021-10-14 | 2024-07-09 | Arsenal Biosciences Inc | Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica. |
| CA3242360A1 (en) * | 2021-12-10 | 2023-06-15 | Beam Therapeutics Inc. | Modified immune cells and methods of using the same |
| WO2023137457A2 (en) * | 2022-01-13 | 2023-07-20 | Spotlight Therapeutics | Immune response specific guide rnas and uses thereof |
| WO2023141590A2 (en) | 2022-01-21 | 2023-07-27 | Mammoth Biosciences, Inc. | Effector proteins and methods of use |
| US20260083846A1 (en) * | 2022-05-19 | 2026-03-26 | Lyell Immunopharma, Inc. | Polynucleotides targeting nr4a3 and uses thereof |
| JP2025532585A (ja) * | 2022-09-16 | 2025-10-01 | アーセナル バイオサイエンシズ インコーポレイテッド | 組み合わせ遺伝子摂動を有する免疫細胞 |
| TW202442689A (zh) | 2023-03-03 | 2024-11-01 | 美商亞森諾生物科學公司 | 靶向psma及ca9之系統 |
| WO2024197020A2 (en) * | 2023-03-21 | 2024-09-26 | Beam Therapeutics Inc. | Immunosuppressant-resistant modified allogeneic modified immune cells and methods for use thereof |
| WO2025126049A2 (en) * | 2023-12-11 | 2025-06-19 | Crispr Therapeutics Ag | Multiplex gene editing |
| WO2026019758A2 (en) * | 2024-07-16 | 2026-01-22 | The University Of North Carolina At Chapel Hill | Engineered cas9 endonucleases with enhanced editing efficiency |
| WO2026077659A1 (en) * | 2024-09-17 | 2026-04-16 | Institut National de la Santé et de la Recherche Médicale | Enrichment of genetically modified hematopoietic stem cells through epigenome editing |
Family Cites Families (244)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997006121A1 (en) | 1995-08-04 | 1997-02-20 | Jennings, Norman, T. | Compositions and method for controlling odor in organic waste material |
| GB9600384D0 (en) | 1996-01-09 | 1996-03-13 | Nyfotek As | Dna glycosylases |
| JP2003514564A (ja) | 1999-11-24 | 2003-04-22 | エムシーエス マイクロ キャリア システムズ ゲーエムベーハー | 核局在化シグナルまたはタンパク質導入領域の多量体を含むポリペプチド、および分子を細胞内へ移入するためのその使用法 |
| US20040003420A1 (en) | 2000-11-10 | 2004-01-01 | Ralf Kuhn | Modified recombinase |
| US20050222030A1 (en) | 2001-02-21 | 2005-10-06 | Anthony Allison | Modified annexin proteins and methods for preventing thrombosis |
| CA2439472A1 (en) | 2001-02-27 | 2002-09-06 | University Of Rochester | Methods and compositions for modifying apolipoprotein b mrna editing |
| AU2002330714A1 (en) | 2001-05-30 | 2003-01-02 | Biomedical Center | In silico screening for phenotype-associated expressed sequences |
| US7300829B2 (en) | 2003-06-02 | 2007-11-27 | Applied Materials, Inc. | Low temperature process for TFT fabrication |
| WO2010132092A2 (en) | 2009-05-12 | 2010-11-18 | The Scripps Research Institute | Cytidine deaminase fusions and related methods |
| US20110104787A1 (en) | 2009-11-05 | 2011-05-05 | President And Fellows Of Harvard College | Fusion Peptides That Bind to and Modify Target Nucleic Acid Sequences |
| US20130011380A1 (en) | 2009-12-18 | 2013-01-10 | Blau Helen M | Use of Cytidine Deaminase-Related Agents to Promote Demethylation and Cell Reprogramming |
| WO2012004778A1 (en) | 2010-07-09 | 2012-01-12 | Ecole Polytechnique Federale De Lausanne (Epfl) | Method for in-vitro monitoring of neuronal disorders and use thereof |
| DK2699593T4 (da) | 2011-04-20 | 2021-02-08 | Univ Washington Through Its Center For Commercialization | Beta-2 mikroglobulin-deficiente celler |
| JP6177780B2 (ja) | 2011-09-28 | 2017-08-09 | エラ、ビオテック、ソシエダッド、アノニマEra Biotech, S.A. | スプリットインテインおよびその使用 |
| CN103088008B (zh) | 2011-10-31 | 2014-08-20 | 中国科学院微生物研究所 | 胞苷脱氨酶及其编码基因和它们的应用 |
| BR112014020502A2 (pt) | 2012-02-22 | 2019-09-24 | Univ Pennsylvania | sequência de ácido nucleico isolada, receptor quimérico de antígeno isolado, célula, vetor, e, métodos para estimular uma resposta imune, para fornecer uma imunidade antitumoral, para tratamento de um mamífero, para gerar e para expandir uma população de células - t, e para modular a quantidade de citocina secretada por uma célula -t |
| US20160289674A1 (en) | 2012-04-02 | 2016-10-06 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of membrane proteins |
| EP4253409A3 (en) | 2012-04-17 | 2023-12-06 | University of Washington through its Center for Commercialization | Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof |
| ES2728782T3 (es) | 2012-05-25 | 2019-10-28 | Univ California | Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN |
| US20150017136A1 (en) | 2013-07-15 | 2015-01-15 | Cellectis | Methods for engineering allogeneic and highly active t cell for immunotherapy |
| WO2013188037A2 (en) | 2012-06-11 | 2013-12-19 | Agilent Technologies, Inc | Method of adaptor-dimer subtraction using a crispr cas6 protein |
| PT2877490T (pt) | 2012-06-27 | 2019-02-12 | Univ Princeton | Inteínas clivadas, conjugados e suas utilizações |
| DK3363902T3 (da) | 2012-12-06 | 2020-01-02 | Sigma Aldrich Co Llc | Crispr-baseret genommodifikation og -regulering |
| PT2931898E (pt) | 2012-12-12 | 2016-06-16 | Harvard College | Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais |
| US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
| US20140273230A1 (en) | 2013-03-15 | 2014-09-18 | Sigma-Aldrich Co., Llc | Crispr-based genome modification and regulation |
| SI2997141T1 (sl) | 2013-05-13 | 2023-04-28 | Cellectis | CD19 specifični himerni antigenski receptor in njegova uporaba |
| WO2014186686A2 (en) | 2013-05-17 | 2014-11-20 | Two Blades Foundation | Targeted mutagenesis and genome engineering in plants using rna-guided cas nucleases |
| EP3603679B1 (en) | 2013-06-04 | 2022-08-10 | President and Fellows of Harvard College | Rna-guided transcriptional regulation |
| WO2014197748A2 (en) | 2013-06-05 | 2014-12-11 | Duke University | Rna-guided gene editing and gene regulation |
| JP2016528890A (ja) | 2013-07-09 | 2016-09-23 | プレジデント アンド フェローズ オブ ハーバード カレッジ | CRISPR/Cas系を用いるゲノム編集の治療用の使用 |
| CN105517579B (zh) | 2013-07-10 | 2019-11-15 | 哈佛大学校长及研究员协会 | 用于RNA向导的基因调节和编辑的正交Cas9蛋白 |
| US20150044772A1 (en) | 2013-08-09 | 2015-02-12 | Sage Labs, Inc. | Crispr/cas system-based novel fusion protein and its applications in genome editing |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| EP3066118B1 (en) | 2013-11-06 | 2020-01-08 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Alk antibodies, conjugates, and chimeric antigen receptors, and their use |
| EP3835419A1 (en) | 2013-12-12 | 2021-06-16 | The Regents of The University of California | Methods and compositions for modifying a single stranded target nucleic acid |
| US20150166984A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
| CN111206032B (zh) | 2013-12-12 | 2024-07-19 | 布罗德研究所有限公司 | 用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用 |
| ES2918501T3 (es) | 2013-12-19 | 2022-07-18 | Novartis Ag | Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos |
| WO2015092024A2 (en) | 2013-12-20 | 2015-06-25 | Cellectis | Method of engineering multi-input signal sensitive t cell for immunotherapy |
| EP3613854A1 (en) | 2014-03-05 | 2020-02-26 | National University Corporation Kobe University | Genomic sequence modification method for specifically converting nucleic acid bases of targeted dna sequence, and molecular complex for use in same |
| RU2752933C2 (ru) | 2014-03-11 | 2021-08-11 | Селлектис | Способ создания т-клеток, пригодных для аллогенной трансплантации |
| CN122399016A (zh) | 2014-03-15 | 2026-07-17 | 诺华股份有限公司 | 使用嵌合抗原受体治疗癌症 |
| WO2015191693A2 (en) | 2014-06-10 | 2015-12-17 | Massachusetts Institute Of Technology | Method for gene editing |
| US10738278B2 (en) | 2014-07-15 | 2020-08-11 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| WO2016016343A1 (en) | 2014-07-31 | 2016-02-04 | Cellectis | Ror1 specific multi-chain chimeric antigen receptor |
| WO2016019300A1 (en) | 2014-07-31 | 2016-02-04 | Novartis Ag | Subset-optimized chimeric antigen receptor-containing t-cells |
| US10450584B2 (en) | 2014-08-28 | 2019-10-22 | North Carolina State University | Cas9 proteins and guiding features for DNA targeting and genome editing |
| ES2688035T3 (es) | 2014-08-29 | 2018-10-30 | Gemoab Monoclonals Gmbh | Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes |
| AU2015332533B2 (en) | 2014-10-14 | 2018-08-30 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same |
| US20170239294A1 (en) | 2014-10-15 | 2017-08-24 | Novartis Ag | Compositions and methods for treating b-lymphoid malignancies |
| EP3212221B1 (en) | 2014-10-29 | 2023-12-06 | Massachusetts Eye & Ear Infirmary | Efficient delivery of therapeutic molecules in vitro and in vivo |
| KR102546296B1 (ko) | 2014-10-31 | 2023-06-21 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도 |
| JP6153180B2 (ja) | 2014-11-04 | 2017-06-28 | 国立大学法人神戸大学 | 脱塩基反応により標的化したdna配列に特異的に変異を導入する、ゲノム配列の改変方法、並びにそれに用いる分子複合体 |
| MA40921A (fr) | 2014-11-05 | 2017-09-12 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation |
| CA2967222C (en) | 2014-11-12 | 2023-10-31 | Rinat Neuroscience Corp. | Inhibitory chimeric antigen receptors |
| US10383929B2 (en) | 2014-12-12 | 2019-08-20 | Bluebird Bio, Inc. | BCMA chimeric antigen receptors |
| AU2015367378A1 (en) | 2014-12-17 | 2017-06-15 | Proqr Therapeutics Ii B.V. | Targeted RNA editing |
| AU2015364286B2 (en) | 2014-12-20 | 2021-11-04 | Arc Bio, Llc | Compositions and methods for targeted depletion, enrichment, and partitioning of nucleic acids using CRISPR/Cas system proteins |
| US11459390B2 (en) | 2015-01-16 | 2022-10-04 | Novartis Ag | Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor |
| MA41613A (fr) | 2015-02-23 | 2018-01-02 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs |
| CA2977106A1 (en) | 2015-02-27 | 2016-09-01 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof |
| AU2016226077B2 (en) | 2015-03-03 | 2021-12-23 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases with altered PAM specificity |
| WO2016142532A1 (en) | 2015-03-11 | 2016-09-15 | Cellectis | Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients |
| BR112017020750A2 (en) | 2015-03-27 | 2018-06-26 | President And Fellows Of Harvard College | modified t-cells and methods of producing and using them |
| EP4019975A1 (en) | 2015-04-24 | 2022-06-29 | Editas Medicine, Inc. | Evaluation of cas9 molecule/guide rna molecule complexes |
| EP3294342A4 (en) | 2015-05-08 | 2018-11-07 | President and Fellows of Harvard College | Universal donor stem cells and related methods |
| US20180291372A1 (en) | 2015-05-14 | 2018-10-11 | Massachusetts Institute Of Technology | Self-targeting genome editing system |
| CN106011104B (zh) | 2015-05-21 | 2019-09-27 | 清华大学 | 利用拆分Cas系统进行基因编辑和表达调控方法 |
| US20160348074A1 (en) | 2015-05-29 | 2016-12-01 | Agenovir Corporation | Methods and compositions for treating cells for transplant |
| MX2017015239A (es) | 2015-05-29 | 2018-02-19 | Juno Therapeutics Inc | Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas. |
| AU2016279062A1 (en) | 2015-06-18 | 2019-03-28 | Omar O. Abudayyeh | Novel CRISPR enzymes and systems |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| WO2016205759A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation |
| EP3929287A3 (en) | 2015-06-18 | 2022-04-13 | The Broad Institute, Inc. | Crispr enzyme mutations reducing off-target effects |
| JP7033453B2 (ja) | 2015-06-30 | 2022-03-10 | セレクティス | 特異的エンドヌクレアーゼを使用した遺伝子不活化によってnk細胞の機能性を改善する方法 |
| EP3957731A1 (en) | 2015-07-15 | 2022-02-23 | Rutgers, The State University of New Jersey | Nuclease-independent targeted gene editing platform and uses thereof |
| US20170020922A1 (en) | 2015-07-16 | 2017-01-26 | Batu Biologics Inc. | Gene editing for immunological destruction of neoplasia |
| US9512446B1 (en) | 2015-08-28 | 2016-12-06 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases |
| US11242375B2 (en) | 2015-09-04 | 2022-02-08 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use |
| US11008555B2 (en) | 2015-09-17 | 2021-05-18 | The Regents Of The University Of California | Variant Cas9 polypeptides comprising internal insertions |
| CA2999070A1 (en) | 2015-09-17 | 2017-03-23 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| WO2017070632A2 (en) | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| MX2018005618A (es) | 2015-11-05 | 2018-08-01 | Juno Therapeutics Inc | Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados. |
| US11020429B2 (en) | 2015-11-05 | 2021-06-01 | Juno Therapeutics, Inc. | Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy |
| US11866727B2 (en) | 2015-11-06 | 2024-01-09 | Crispr Therapeutics Ag | Materials and methods for treatment of glycogen storage disease type 1A |
| WO2017093804A2 (en) | 2015-12-01 | 2017-06-08 | Crispr Therapeutics Ag | Materials and methods for treatment of alpha-1 antitrypsin deficiency |
| WO2017093969A1 (en) | 2015-12-04 | 2017-06-08 | Novartis Ag | Compositions and methods for immunooncology |
| WO2017132580A2 (en) | 2016-01-29 | 2017-08-03 | The Trustees Of Princeton University | Split inteins with exceptional splicing activity |
| MX2018010484A (es) | 2016-03-04 | 2019-01-10 | Editas Medicine Inc | Métodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cáncer. |
| EP3433364A1 (en) | 2016-03-25 | 2019-01-30 | Editas Medicine, Inc. | Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency |
| ES3030658T3 (en) | 2016-03-30 | 2025-07-01 | Intellia Therapeutics Inc | Lipid nanoparticle formulations for crispr/cas components |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| CA3020993A1 (en) | 2016-04-14 | 2017-10-19 | Bluebird Bio, Inc. | Salvage chimeric antigen receptor systems |
| CA3026110A1 (en) | 2016-04-19 | 2017-11-02 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
| KR20260004568A (ko) | 2016-04-19 | 2026-01-08 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신규한 crispr 효소 및 시스템 |
| SG10202109385QA (en) | 2016-07-05 | 2021-10-28 | Univ Johns Hopkins | Crispr/cas9-based compositions and methods for treating retinal degenerations |
| WO2018020323A2 (en) | 2016-07-25 | 2018-02-01 | Crispr Therapeutics Ag | Materials and methods for treatment of fatty acid disorders |
| US12350349B2 (en) | 2016-08-03 | 2025-07-08 | Washington University | Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors |
| WO2018027078A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
| AU2017308889B2 (en) | 2016-08-09 | 2023-11-09 | President And Fellows Of Harvard College | Programmable Cas9-recombinase fusion proteins and uses thereof |
| US11352647B2 (en) | 2016-08-17 | 2022-06-07 | The Broad Institute, Inc. | Crispr enzymes and systems |
| WO2018041973A1 (en) | 2016-09-01 | 2018-03-08 | Proqr Therapeutics Ii B.V. | Chemically modified single-stranded rna-editing oligonucleotides |
| KR20240007715A (ko) | 2016-10-14 | 2024-01-16 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
| MX2019005277A (es) | 2016-11-04 | 2019-09-27 | Bluebird Bio Inc | Composiciones de celulas t con car anti-bcma. |
| US11180778B2 (en) | 2016-11-11 | 2021-11-23 | The Regents Of The University Of California | Variant RNA-guided polypeptides and methods of use |
| CN107043779B (zh) | 2016-12-01 | 2020-05-12 | 中国农业科学院作物科学研究所 | 一种CRISPR/nCas9介导的定点碱基替换在植物中的应用 |
| EP3551757A1 (en) | 2016-12-08 | 2019-10-16 | Intellia Therapeutics, Inc. | Modified guide rnas |
| GB201622044D0 (en) | 2016-12-22 | 2017-02-08 | Ucl Business Plc | T cell-targeted T cells |
| JP7383478B2 (ja) | 2016-12-22 | 2023-11-20 | インテリア セラピューティクス,インコーポレイテッド | アルファ1アンチトリプシン欠乏症を治療するための組成物および方法 |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| KR102569848B1 (ko) | 2016-12-23 | 2023-08-25 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Pcsk9의 유전자 편집 |
| EP3565608A4 (en) | 2017-01-05 | 2020-12-16 | Rutgers, The State University of New Jersey | TARGETED GENE EDITING PLATFORM INDEPENDENT OF BICATENARY DNA BREAKAGE AND ITS USES |
| AU2018208614A1 (en) * | 2017-01-10 | 2019-07-11 | The General Hospital Corporation | Modified T cells and methods of their use |
| US11535662B2 (en) | 2017-01-26 | 2022-12-27 | Novartis Ag | CD28 compositions and methods for chimeric antigen receptor therapy |
| WO2018152197A1 (en) | 2017-02-15 | 2018-08-23 | Massachusetts Institute Of Technology | Dna writers, molecular recorders and uses thereof |
| KR102709603B1 (ko) | 2017-02-28 | 2024-09-27 | 보르 바이오파마 인크. | 계통 특이적 단백질의 억제를 위한 조성물 및 방법 |
| KR20190123328A (ko) | 2017-03-09 | 2019-10-31 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 암 백신 |
| CN110914310A (zh) | 2017-03-10 | 2020-03-24 | 哈佛大学的校长及成员们 | 胞嘧啶至鸟嘌呤碱基编辑器 |
| IL306092A (en) | 2017-03-23 | 2023-11-01 | Harvard College | Nucleic base editors that include nucleic acid programmable DNA binding proteins |
| EP3600357A4 (en) | 2017-03-31 | 2021-01-06 | The Board of Trustees of the Leland Stanford Junior University | METHODS OF TREATING T-LYMPHOCYTE DEPLETION BY INHIBITING OR MODULATING T-LYMPHOCYTE RECEPTOR SIGNALING |
| CN106916852B (zh) | 2017-04-13 | 2020-12-04 | 上海科技大学 | 一种碱基编辑系统及其构建和应用方法 |
| WO2018195545A2 (en) | 2017-04-21 | 2018-10-25 | The General Hospital Corporation | Variants of cpf1 (cas12a) with altered pam specificity |
| PL3618842T3 (pl) | 2017-05-01 | 2024-02-19 | Juno Therapeutics, Inc. | Kombinacja terapii komórkowej i związku immunomodulującego |
| EP3625342B1 (en) | 2017-05-18 | 2022-08-24 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
| KR102678809B1 (ko) | 2017-05-18 | 2024-06-26 | 더 브로드 인스티튜트, 인코퍼레이티드 | 표적화된 핵산 편집을 위한 시스템, 방법 및 조성물 |
| WO2018218066A1 (en) | 2017-05-24 | 2018-11-29 | The Regents Of The University Of California | Cmv vaccine and method of making and using the same |
| CA3063733A1 (en) | 2017-05-25 | 2018-11-29 | The General Hospital Corporation | Base editors with improved precision and specificity |
| CA3067244A1 (en) | 2017-06-12 | 2018-12-20 | Children's Healthcare Of Atlanta, Inc. | T-cell antigen targeted chimeric antigen receptor (car) and uses in cell therapies |
| CN111328290A (zh) | 2017-06-26 | 2020-06-23 | 博德研究所 | 用于靶向核酸编辑的基于crispr/cas-腺嘌呤脱氨酶的组合物、系统和方法 |
| WO2019005886A1 (en) | 2017-06-26 | 2019-01-03 | The Broad Institute, Inc. | CRISPR / CAS-CYTIDINE DEAMINASE COMPOSITIONS, SYSTEMS AND METHODS FOR TARGETED EDITING OF NUCLEIC ACIDS |
| US10392616B2 (en) | 2017-06-30 | 2019-08-27 | Arbor Biotechnologies, Inc. | CRISPR RNA targeting enzymes and systems and uses thereof |
| CA3069527A1 (en) | 2017-07-12 | 2019-01-17 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for treatment of cancers harboring an h3k27m mutation |
| WO2019014665A1 (en) | 2017-07-14 | 2019-01-17 | Dana-Farber Cancer Institute, Inc. | MODULATION OF BIOMARKERS TO INCREASE ANTITUMOR IMMUNITY AND IMPROVE THE EFFECTIVENESS OF ANTICANCER IMMUNOTHERAPY |
| EP3658573A1 (en) | 2017-07-28 | 2020-06-03 | President and Fellows of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace) |
| WO2019040650A1 (en) | 2017-08-23 | 2019-02-28 | The General Hospital Corporation | GENETICALLY MODIFIED CRISPR-CAS9 NUCLEASES HAVING MODIFIED PAM SPECIFICITY |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| IL316453A (en) | 2017-10-06 | 2024-12-01 | Univ Oregon Health & Science | RNA editing agents and methods |
| CA3082251A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Uses of adenosine base editors |
| EP3723774A4 (en) | 2017-12-15 | 2021-09-08 | The Board of Trustees of the Leland Stanford Junior University | COMPOSITIONS AND METHODS OF INHIBITION OF T-CELL EXHAUSTATION |
| AR114014A1 (es) | 2017-12-22 | 2020-07-08 | Inst Genetics & Developmental Biology Cas | Sistema de edición de bases y método basado en proteína cpf1 |
| CA3090793C (en) | 2018-02-16 | 2024-10-08 | Kite Pharma, Inc. | MODIFIED MULTIPOTENTED STEM CELLS, AND METHODS OF PREPARATION AND USE |
| CN112292139B (zh) * | 2018-03-13 | 2024-03-08 | 明尼苏达大学董事会 | 使用Cas9碱基编辑器的淋巴造血改造 |
| US20210363518A1 (en) | 2018-03-19 | 2021-11-25 | University Of Massachusetts | Modified guide rnas for crispr genome editing |
| EP3781176A4 (en) | 2018-04-09 | 2022-05-25 | The Trustees of the University of Pennsylvania | METHODS AND COMPOSITIONS USING A VIRAL VECTOR FOR THE EXPRESSION OF A TRANSGENE AND AN EFFECTOR |
| WO2019210207A2 (en) | 2018-04-27 | 2019-10-31 | The Trustees Of The University Of Pennsylvania | Chimeric antigen receptor t regulatory cells for the treatment of atherosclerosis |
| KR102959497B1 (ko) | 2018-05-11 | 2026-05-04 | 빔 테라퓨틱스, 인크. | 프로그래밍가능한 염기 편집기 시스템을 이용하여 병원성 돌연변이를 억제하는 방법 |
| WO2019217942A1 (en) | 2018-05-11 | 2019-11-14 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| KR102853088B1 (ko) | 2018-05-11 | 2025-09-02 | 빔 테라퓨틱스, 인크. | 프로그래밍가능한 염기 편집기 시스템을 이용하여 단일염기다형성을 편집하는 방법 |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| CN110616189B (zh) | 2018-06-20 | 2022-02-18 | 西安桑尼赛尔生物医药有限公司 | 通用型靶向cd19抗原嵌合受体t细胞的制备及其应用 |
| CN108753823B (zh) | 2018-06-20 | 2022-09-23 | 李广磊 | 利用碱基编辑技术实现基因敲除的方法及其应用 |
| WO2020010239A1 (en) | 2018-07-06 | 2020-01-09 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric antigen receptor polypeptides and methods of using same |
| CN108949825A (zh) | 2018-07-30 | 2018-12-07 | 苏州茂行生物科技有限公司 | 一种靶向her2的car-t细胞的制备方法及应用 |
| KR102894715B1 (ko) | 2018-08-03 | 2025-12-03 | 빔 테라퓨틱스, 인크. | 핵산 표적 서열을 변형시키기 위한 다중-이펙터 핵염기 편집기 및 이를 이용하는 방법 |
| WO2020041751A1 (en) | 2018-08-23 | 2020-02-27 | The Broad Institute, Inc. | Cas9 variants having non-canonical pam specificities and uses thereof |
| KR20210055733A (ko) | 2018-09-07 | 2021-05-17 | 빔 테라퓨틱스, 인크. | 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법 |
| CN109295186B (zh) | 2018-09-30 | 2023-10-03 | 中山大学 | 一种基于全基因组测序检测腺嘌呤单碱基编辑系统脱靶效应的方法及其在基因编辑中的应用 |
| KR20210094609A (ko) | 2018-11-28 | 2021-07-29 | 포티 세븐, 인코포레이티드 | 절제 레짐에 대해 저항성인 유전적으로 변형된 hspc |
| EP3887521A1 (en) | 2018-11-29 | 2021-10-06 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
| CA3121911A1 (en) | 2018-12-06 | 2020-06-11 | The Board Of Trustees Of The Leland Stanford Junior University | Regulatable cell surface receptors and related compositions and methods |
| AU2019404302A1 (en) | 2018-12-19 | 2021-08-05 | The Trustees Of The University Of Pennsylvania | Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor t cells against t cell lymphomas and leukemias |
| KR20210116526A (ko) | 2019-01-16 | 2021-09-27 | 빔 테라퓨틱스, 인크. | 증진된 항-신생물 활성 및 면역억제 내성을 갖는 변형된 면역 세포 |
| CN109706121A (zh) * | 2019-01-25 | 2019-05-03 | 苏州茂行生物科技有限公司 | 一种基于碱基编辑的通用型car-t细胞及其制备方法和应用 |
| JP7646552B2 (ja) | 2019-01-31 | 2025-03-17 | ビーム セラピューティクス インク. | 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ |
| AU2020216484A1 (en) | 2019-01-31 | 2021-07-29 | Beam Therapeutics Inc. | Nucleobase editors having reduced off-target deamination and methods of using same to modify a nucleobase target sequence |
| WO2020163396A1 (en) | 2019-02-04 | 2020-08-13 | The General Hospital Corporation | Adenine dna base editor variants with reduced off-target rna editing |
| US20220098593A1 (en) | 2019-02-13 | 2022-03-31 | Beam Therapeutics Inc. | Splice acceptor site disruption of a disease-associated gene using adenosine deaminase base editors, including for the treatment of genetic disease |
| EP3924479A4 (en) | 2019-02-13 | 2023-01-25 | Beam Therapeutics, Inc. | ADENOSINE DEAMINASE BASE EDITORS AND METHODS OF USING THEM TO MODIFY A NUCLEOBASE IN A TARGET SEQUENCE |
| CN114096666B (zh) | 2019-02-13 | 2025-03-18 | 比姆医疗股份有限公司 | 治疗血红素病变的组合物和方法 |
| US12600971B2 (en) | 2019-02-13 | 2026-04-14 | Beam Therapeutics Inc. | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| WO2020168135A1 (en) | 2019-02-13 | 2020-08-20 | Beam Therapeutics Inc. | Compositions and methods for treating alpha-1 antitrypsin deficiency |
| CN114040970B (zh) | 2019-02-13 | 2024-09-27 | 比姆医疗股份有限公司 | 使用腺苷脱氨酶碱基编辑器编辑疾病相关基因的方法,包括遗传性疾病的治疗 |
| US20220127594A1 (en) | 2019-02-13 | 2022-04-28 | Beam Therapeutics Inc. | Compositions and methods for treating glycogen storage disease type 1a |
| BR112021016046A2 (pt) | 2019-02-15 | 2021-11-09 | Editas Medicine Inc | Células assassinas naturais modificadas (nk) para imunoterapia |
| WO2020176897A1 (en) | 2019-02-28 | 2020-09-03 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric antigen receptors and uses thereof |
| TW202042824A (zh) | 2019-03-27 | 2020-12-01 | 賓夕法尼亞大學董事會 | Tn-MUC1嵌合抗原受體(CAR)T細胞療法 |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| WO2020227446A1 (en) | 2019-05-07 | 2020-11-12 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of polypeptides and chimeric antigen receptors via hinge domains |
| WO2020227447A1 (en) | 2019-05-07 | 2020-11-12 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric antigen receptors targeting glypican-2 |
| US20200370013A1 (en) | 2019-05-20 | 2020-11-26 | The Trustees Of The University Of Pennsylvania | Engineered Expression of Cell Surface and Secreted Sialidase by CAR T Cells for Increased Efficacy in Solid Tumors |
| WO2020236982A1 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Aav delivery of nucleobase editors |
| JP7679311B2 (ja) | 2019-05-21 | 2025-05-19 | ビーム セラピューティクス インク. | プログラム可能塩基エディターシステムを用いた一塩基多型編集法 |
| KR20220015382A (ko) | 2019-05-29 | 2022-02-08 | 큐 바이오파마, 인크. | 다량체 t-세포 조절 폴리펩타이드 및 이의 사용 방법 |
| AU2020322021A1 (en) | 2019-07-30 | 2022-02-10 | Pairwise Plants Services, Inc. | Morphogenic regulators and methods of using the same |
| KR102258713B1 (ko) | 2019-07-31 | 2021-05-31 | 한양대학교 산학협력단 | 사이토신 염기교정용 조성물 및 이의 용도 |
| AU2020336969B2 (en) | 2019-08-29 | 2024-12-05 | Beam Therapeutics Inc. | Compositions and methods for non-toxic conditioning |
| US20220290121A1 (en) | 2019-08-30 | 2022-09-15 | The General Hospital Corporation | Combinatorial Adenine and Cytosine DNA Base Editors |
| AU2020344547A1 (en) | 2019-09-09 | 2022-03-24 | Beam Therapeutics Inc. | Novel nucleobase editors and methods of using same |
| AU2020466994B2 (en) | 2019-09-17 | 2026-05-28 | Rutgers, The State University Of New Jersey | Highly efficient DNA base editors mediated by RNA-aptamer recruitment for targeted genome modification and uses thereof |
| US12594301B2 (en) | 2019-09-27 | 2026-04-07 | Beam Therapeutics Inc. | Compositions and methods for treatment of liquid cancers |
| JP2022552265A (ja) | 2019-10-11 | 2022-12-15 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 調節可能な細胞局在化のための組換えポリペプチド |
| US11591607B2 (en) | 2019-10-24 | 2023-02-28 | Pairwise Plants Services, Inc. | Optimized CRISPR-Cas nucleases and base editors and methods of use thereof |
| CN114867852A (zh) | 2019-10-30 | 2022-08-05 | 成对植物服务股份有限公司 | V型crispr-cas碱基编辑器及其使用方法 |
| WO2021087356A1 (en) | 2019-11-01 | 2021-05-06 | The Trustees Of The University Of Pennsylvania | Fibronectin targeting chimeric antigen receptors (cars) |
| EP4061927A4 (en) | 2019-11-20 | 2024-11-13 | Cartherics Pty. Ltd. | METHOD FOR PROVIDING IMMUNE CELLS WITH ENHANCED FUNCTION |
| WO2021108717A2 (en) | 2019-11-26 | 2021-06-03 | The Broad Institute, Inc | Systems and methods for evaluating cas9-independent off-target editing of nucleic acids |
| CN114929250A (zh) | 2019-12-18 | 2022-08-19 | 爱迪塔斯医药公司 | 用于疗法的经工程化的细胞 |
| US20210230246A1 (en) | 2020-01-15 | 2021-07-29 | The Trustees Of The University Of Pennsylvania | Use of inhibitory chimeric receptors to prevent t cell-induced blood brain barrier damage |
| WO2021158999A1 (en) | 2020-02-05 | 2021-08-12 | The Broad Institute, Inc. | Gene editing methods for treating spinal muscular atrophy |
| US20230235309A1 (en) | 2020-02-05 | 2023-07-27 | The Broad Institute, Inc. | Adenine base editors and uses thereof |
| CN115698285A (zh) | 2020-02-14 | 2023-02-03 | 小利兰·斯坦福大学董事会 | 具有cd2激活的嵌合抗原受体 |
| BR112022017732A2 (pt) | 2020-03-04 | 2023-01-17 | Suzhou Qi Biodesign Biotechnology Company Ltd | Sistema aperfeiçoado de edição de base de citosina |
| WO2021188840A1 (en) | 2020-03-19 | 2021-09-23 | Rewrite Therapeutics, Inc. | Methods and compositions for directed genome editing |
| EP4132951A4 (en) | 2020-04-09 | 2025-06-11 | Verve Therapeutics, Inc. | CHEMICALLY MODIFIED GENE EDITING GUIDE RNAS WITH CAS12B |
| EP4179079A1 (en) | 2020-07-10 | 2023-05-17 | Horizon Discovery Limited | Method for producing genetically modified cells |
| JP7890972B2 (ja) | 2020-07-15 | 2026-07-15 | ライフ エディット セラピューティクス,インコーポレイティド | ウラシル安定化タンパク質並びにその活性断片及びバリアント並びに使用方法 |
| CA3192224A1 (en) | 2020-09-11 | 2022-03-17 | Jyun-Liang LIN | Base editing enzymes |
| EP4211235A2 (en) | 2020-09-11 | 2023-07-19 | Lifeedit Therapeutics, Inc. | Dna modifying enzymes and active fragments and variants thereof and methods of use |
| WO2022061115A1 (en) * | 2020-09-18 | 2022-03-24 | Vor Biopharma Inc. | Compositions and methods for cd7 modification |
| AU2021347359A1 (en) | 2020-09-25 | 2023-05-18 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
| US20230383277A1 (en) | 2020-10-14 | 2023-11-30 | Beam Therapeutics Inc. | Compositions and methods for treating glycogen storage disease type 1a |
| IT202000028688A1 (it) | 2020-11-27 | 2022-05-27 | Consiglio Nazionale Ricerche | Varianti della citidina deaminasi per l’editazione di basi |
| EP4274902A4 (en) | 2021-01-05 | 2025-04-16 | Revvity Discovery Limited | Guide RNA designs and complexes for tracless V-CAS systems |
| US20240060088A1 (en) | 2021-01-05 | 2024-02-22 | Horizon Discovery Limited | Guide RNA Designs and Complexes for Type V Cas Systems |
| CA3207144A1 (en) | 2021-01-05 | 2022-07-14 | Horizon Discovery Limited | Method for producing genetically modified cells |
| WO2022150706A2 (en) | 2021-01-08 | 2022-07-14 | The General Hospital Corporation | Genome editing approaches to treat spinal muscular atrophy |
| JP2024507533A (ja) | 2021-02-19 | 2024-02-20 | ビーム・セラピューティクス・インコーポレイテッド | 遺伝子治療のための組み換え狂犬病ウイルス |
| BR112023019539A2 (pt) | 2021-03-26 | 2023-12-05 | Beam Therapeutics Inc | Variantes de adenosina desaminase e usos das mesmas |
| WO2022272292A2 (en) | 2021-06-23 | 2022-12-29 | Editas Medicine, Inc. | Engineered cells for therapy |
| WO2023279118A2 (en) | 2021-07-02 | 2023-01-05 | University Of Maryland, College Park | Cytidine deaminases and methods of genome editing using the same |
| CA3225808A1 (en) | 2021-07-16 | 2023-01-19 | David R. Liu | Context-specific adenine base editors and uses thereof |
| EP4388105A4 (en) | 2021-08-16 | 2026-02-11 | Beam Therapeutics Inc | Persistent Allogeneic Modified Immune Cells and Their Methods of Use |
| EP4396207A4 (en) | 2021-09-03 | 2025-07-16 | Univ Chicago | POLYPEPTIDES AND METHODS FOR MODIFYING NUCLEIC ACIDS |
| GB2702733A (en) | 2021-09-22 | 2026-06-24 | Verve Therapeutics Inc | Gene editing of PCSK9 or ANGPTL3 and compositions and methods of using same for treatment of disease |
| US20230105319A1 (en) | 2021-09-24 | 2023-04-06 | Crispr Therapeutics Ag | PRODRUG INCORPORATED sgRNA SYNTHESIS |
| CA3242360A1 (en) | 2021-12-10 | 2023-06-15 | Beam Therapeutics Inc. | Modified immune cells and methods of using the same |
| WO2023125814A1 (zh) | 2021-12-29 | 2023-07-06 | 华东师范大学 | 腺嘌呤脱氨酶及其应用 |
| WO2023155901A1 (en) | 2022-02-17 | 2023-08-24 | Correctsequence Therapeutics | Mutant cytidine deaminases with improved editing precision |
| CN114634923B (zh) | 2022-04-07 | 2024-02-23 | 尧唐(上海)生物科技有限公司 | 腺苷脱氨酶、碱基编辑器融合蛋白、碱基编辑器系统及用途 |
| JP2025517515A (ja) | 2022-05-26 | 2025-06-05 | ユーシービー バイオファルマ エスアールエル | 新規核酸編集タンパク質 |
| EP4532697A2 (en) | 2022-06-03 | 2025-04-09 | Beam Therapeutics Inc. | Modified regulatory t cells and methods of using the same |
| EP4540378A1 (en) | 2022-06-20 | 2025-04-23 | CRISPR Therapeutics AG | Base editing proteins and uses thereof |
| JP2025520697A (ja) | 2022-06-23 | 2025-07-03 | ビーエーエスエフ アグリカルチュラル ソリューションズ ユーエス エルエルシー | 多様化塩基編集 |
| EP4544035A4 (en) | 2022-06-27 | 2026-06-24 | Beam Therapeutics Inc | ADENOSINE DEAMINASE BASIC EDITORS AND THEIR METHODS OF USE |
| AU2023325079A1 (en) | 2022-08-16 | 2025-02-13 | President And Fellows Of Harvard College | Evolved cytosine deaminases and methods of editing dna using same |
| WO2024063273A1 (en) | 2022-09-23 | 2024-03-28 | Institute For Basic Science | Novel adenine deaminase variants and a method for base editing using the same |
| CN120435553A (zh) | 2022-09-26 | 2025-08-05 | 比姆医疗股份有限公司 | 合成多肽及其用途 |
| WO2024179426A2 (en) | 2023-02-28 | 2024-09-06 | Accuredit Therapeutics (Suzhou) Co., Ltd. | Deaminases for use in base editing |
| WO2024226156A1 (en) | 2023-04-27 | 2024-10-31 | University Of Massachusetts | Cas-embedded cytidine deaminase ribonucleoprotein complexes having improved base editing specificity and efficiency |
| KR20260007576A (ko) | 2023-04-28 | 2026-01-14 | 빔 테라퓨틱스, 인크. | 변형된 가이드 rna |
| CN121889499A (zh) | 2023-06-15 | 2026-04-17 | 比姆医疗股份有限公司 | 用于治疗α1-抗胰蛋白酶缺乏症的方法和组合物 |
| CN117965505A (zh) | 2023-06-28 | 2024-05-03 | 微光基因(苏州)有限公司 | 工程化的腺苷脱氨酶及碱基编辑器 |
-
2020
- 2020-09-25 US US17/762,690 patent/US12594301B2/en active Active
- 2020-09-25 EP EP20868560.2A patent/EP4034138A4/en active Pending
- 2020-09-25 JP JP2022519460A patent/JP7615134B2/ja active Active
- 2020-09-25 KR KR1020227013872A patent/KR20220090512A/ko active Pending
- 2020-09-25 CN CN202080082229.8A patent/CN115279398B/zh active Active
- 2020-09-25 CA CA3155667A patent/CA3155667A1/en active Pending
- 2020-09-25 WO PCT/US2020/052822 patent/WO2021062227A2/en not_active Ceased
- 2020-09-25 CN CN202510808723.2A patent/CN120905310A/zh active Pending
- 2020-09-25 AU AU2020355222A patent/AU2020355222A1/en active Pending
-
2024
- 2024-12-27 JP JP2024231478A patent/JP7885317B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3155667A1 (en) | 2021-04-01 |
| US12594301B2 (en) | 2026-04-07 |
| WO2021062227A2 (en) | 2021-04-01 |
| US20230021636A1 (en) | 2023-01-26 |
| JP2022549916A (ja) | 2022-11-29 |
| JP7615134B2 (ja) | 2025-01-16 |
| CN120905310A (zh) | 2025-11-07 |
| EP4034138A2 (en) | 2022-08-03 |
| EP4034138A4 (en) | 2024-07-31 |
| CN115279398A (zh) | 2022-11-01 |
| AU2020355222A1 (en) | 2022-03-24 |
| WO2021062227A3 (en) | 2021-05-06 |
| JP7885317B2 (ja) | 2026-07-06 |
| JP2025066723A (ja) | 2025-04-23 |
| CN115279398B (zh) | 2025-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7615134B2 (ja) | 液体がんの治療のための組成物および方法 | |
| AU2022200903C1 (en) | Engineered Cascade components and Cascade complexes | |
| KR102894715B1 (ko) | 핵산 표적 서열을 변형시키기 위한 다중-이펙터 핵염기 편집기 및 이를 이용하는 방법 | |
| KR20210116526A (ko) | 증진된 항-신생물 활성 및 면역억제 내성을 갖는 변형된 면역 세포 | |
| KR20210138603A (ko) | 표적 서열에서 핵염기를 변형하기 위한 아데노신 데아미나제 염기 편집기를 갖는 변형된 면역 세포 | |
| KR102853088B1 (ko) | 프로그래밍가능한 염기 편집기 시스템을 이용하여 단일염기다형성을 편집하는 방법 | |
| KR102724029B1 (ko) | 포유동물 세포의 특성을 변경하기 위한 인공 마이크로-rna 및 이들 생성물의 조성물을 사용한 포유동물 세포의 변형 | |
| KR20210139265A (ko) | 표적 서열에서 핵염기를 변형하기 위한 아데노신 데아미나제 염기 편집기 및 이의 사용 방법 | |
| KR20210124280A (ko) | 표적-이탈 탈아미노화가 감소된 핵염기 편집기 및 이를 이용하여 핵염기 표적 서열을 변형시키는 방법 | |
| KR20210127206A (ko) | 유전성 질환의 치료를 위한 것을 포함하는, 아데노신 데아미나제 염기 편집기를 사용하여 질환-관련 유전자를 편집하는 방법 | |
| AU2018383712B2 (en) | Cpf1-related methods and compositions for gene editing | |
| KR20210125560A (ko) | 유전성 질환의 치료를 위한 것을 포함하는, 아데노신 데아미나제 염기 편집기를 사용한 질환-관련 유전자의 스플라이스 수용체 부위 파괴 | |
| KR20220010540A (ko) | 프로그래밍가능한 염기 편집기 시스템을 이용하여 단일염기다형성을 편집하는 방법 | |
| KR20220076467A (ko) | 신규 핵염기 편집기 및 이의 사용 방법 | |
| KR20230057487A (ko) | 게놈 조정을 위한 방법 및 조성물 | |
| AU2024266710A1 (en) | Compositions and methods for non-toxic conditioning | |
| KR20220038362A (ko) | 재조합 ad35 벡터 및 관련 유전자 요법 개선 | |
| US20240287453A1 (en) | Persistent allogeneic modified immune cells and methods of use thereof | |
| KR20220066289A (ko) | 전사 또는 발현을 가능하게 하는 돌연변이를 편집하기 위한 조성물 및 방법 | |
| CN113748124A (zh) | 工程化以定植肿瘤、肿瘤驻留免疫细胞和肿瘤微环境的免疫刺激性细菌 | |
| KR20210129108A (ko) | 글리코겐 저장 질환 1a형을 치료하기 위한 조성물 및 방법 | |
| CN112673092A (zh) | 工程化的免疫刺激性细菌菌株及其用途 | |
| KR20220019685A (ko) | B형 간염 치료를 위한 조성물 및 방법 | |
| KR20220113943A (ko) | 면역자극성 박테리아 전달 플랫폼 및 치료 제품의 전달을 위한 이의 용도 | |
| KR20230066000A (ko) | 면역자극성 박테리아-기초 백신, 치료제, 및 rna 전달 플랫폼 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |